Karen Cheng

11 papers receiving 648 citations

Karen Cheng's Hit Papers

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study 2018 · 346 citations
3460+2+5Years since publication100200300

Peers

Karen Cheng
Comparison fields: 5 of 55
  • Molecular Medicine 163
  • Applied Microbiology and Biotechnology 39
  • Gastroenterology 62
  • Oncology 213
  • Pulmonary and Respiratory Medicine 198
Replace Minori Matsumoto with:
Minori Matsumoto Japan
Girish S. Naik United States
M. Calvo Spain
Samuel N. Bobrow United States
Elizabeth E. Morgan United States
R. Livingston United States
G. Wesley White United States
Michael May United States
Xiuyu Song China
Magnus Jäderberg United Kingdom
Karen Cheng relative to Minori Matsumoto Japan Minori Matsumoto's profile →
Citations per field
00.5×
Minori Matsumoto · 1×
Citations per year

Countries citing papers authored by Karen Cheng

Since Specialization
Citations

This map shows the geographic impact of Karen Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Cheng more than expected).

Fields of papers citing papers by Karen Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Cheng. The network helps show where Karen Cheng may publish in the future.

Co-authors

The 25 scholars most cited alongside Karen Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karen Cheng Line = papers co-authored together Karen Cheng links everyone, so they are left out of the graph.

All Works

11 of 11 papers shown
#Work
1
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Hit paper breakdown →
2018346
2 200682
3 201959
4 201955
5 201451
6 202021
7 202120
8 201813
9 20219
10 20211
11 20141

About Karen Cheng

Karen Cheng is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Medicine, Endocrinology, Diabetes and Metabolism and Infectious Diseases, having authored 11 papers that have together received 658 indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Diabetes Treatment and Management (2 papers), Advanced Breast Cancer Therapies (2 papers), HER2/EGFR in Cancer Research (1 paper), Nosocomial Infections in ICU (1 paper), Cancer Genomics and Diagnostics (1 paper) and Antimicrobial Resistance in Staphylococcus (1 paper). The work is most often cited by research in Molecular Medicine (163 citations), Applied Microbiology and Biotechnology (39 citations), Gastroenterology (62 citations), Oncology (213 citations) and Pulmonary and Respiratory Medicine (198 citations). Karen Cheng has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Paulo M. Hoff, Haiyan Wu, Jennifer Eng‐Wong, Yoon‐Koo Kang, Lin Shen, Chunyan Song, Atsushi Ohtsu, Katherine Kim, Manish A. Shah and Josep Tabernero. Their work appears in journals such as The Pediatric Infectious Disease Journal, Cancer Research, Clinical Therapeutics, Clinical Microbiology and Infection and Drug Safety.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact